News

Controversial FDA official Dr. Vinay Prasad departs agency
Dr. Vinay Prasad, the controversial critic of the US Food and Drug Administration who took a top role at the regulatory ...
Vinay Prasad resigns as US FDA Biologics Director after less than 3 months
Prasad, an oncologist who previously criticised the FDA and was a fierce critic of US Covid-19 vaccine and mask mandates, had ...
Controversial vaccine official Dr. Vinay Prasad departs FDA
Dr. Vinay Prasad had been serving as the FDA's director of the Center for Biologics Evaluation and Research since May, and ...
Fierce Pharma6d
Vinay Prasad departs FDA amid conservative criticism, controversy over Sarepta gene therapy
Vinay Prasad, M.D., has left the FDA less than three months into the role as director of the Center for Biologics Evaluation ...
Fierce Pharma5d
Vinay Prasad's exit signals FDA's probable slip toward more permissive regulation of cell and gene therapy: analyst
But this time, the unknown is hitting the industry in a different way from when Prasad was tapped to lead CBER less than ...
US FDA's top vaccine official Vinay Prasad leaves agency after 3 months
The U.S. Food and Drug Administration's top vaccine official, Vinay Prasad, has left the agency after just three months as ...
PharmTech5d
FDA Shake-Up: Vinay Prasad Exits Amid Tumult in Biologics Oversight
Prasad’s short FDA tenure brought stricter review standards for gene and COVID vaccines, sparking biotech concern and political backlash.
GEN - Genetic Engineering and Biotechnology News2d
StockWatch: As Prasad Exits FDA, Analysts See Benefit for Sarepta, CGT Stocks
Rare disease and gene therapy stocks, battered in recent months by clinical and commercial setbacks, will likely benefit from ...
FDA’s top vaccine official Vinay Prasad resigns after Loomer campaign against him
Vinay Prasad recently drew outrage from conservatives, including Laura Loomer, who disagreed with his approach to approving ...
BioSpace6d
Prasad Out at CBER Following Sarepta Rollercoaster and Conservative Criticism
The FDA’s dramatic summer continues to unfold as news broke late Tuesday evening that Vinay Prasad will depart the agency, ...
BioSpace5d
New CDER Head Tidmarsh Will Sub In At Biologics Group After Prasad’s Exit
George Tidmarsh has only been at the Center for Drug Evaluation and Research for nine days, but will now add supervision of a ...
Fierce Pharma6d
FDA taps newly appointed George Tidmarsh as acting CBER leader after Vinay Prasad exit
Freshly appointed Center for Drug Evaluation and Research (CDER) leader George Tidmarsh, M.D., Ph.D., will now take on the role of acting director of CBER as well, according to an internal letter from ...